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Abstract
Osteoarthritis (OA) is the most prevalent musculoskeletal disease and a major cause of negative relevant outcomes, asso-
ciated with an ever-increasing societal burden. Pharmaceutical-grade chondroitin sulfate (CS) was repeatedly reported to 
reduce pain and improve function in patients with OA. This article aims to review the evidence for the role of highly purified 
(hp) CS  (Condrosulf®, IBSA) in the treatment of OA. We collected and reported evidence concerning (1) efficacy of hpCS 
800 mg/day in the treatment of OA affecting the knee, hand and hip; (2) efficacy and safety of hpCS 1200 mg/day also in 
the oral gel formulation; (3) the safety profile of hpCS; (4) the difference of hpCS and pharmaceutical-grade formulations 
versus food supplements; (5) pharmacoeconomic added value of hpCS. The data support that hpCS is an effective and safe 
treatment of OA, with its effect already evident at 30 days; in addition, its beneficial action is prolonged, being maintained 
for at least 3 months after the drug is discontinued. Full safety reports’ analyses confirm that CS is safe to use and has almost 
no side effects, in particular, it showed better gastrointestinal tolerance if compared with non-steroidal anti-inflammatory 
drugs (NSAIDs). Moreover, the therapeutic strategy has proved to be cost-effective: treatment with CS reduced the use of 
NSAIDs and their side effects.
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Introduction
Osteoarthritis (OA) is a chronic inflammatory degenera-
tive arthropathy that most commonly affects the joints in 
the knees, hands, feet, and spine; it is also relatively com-
mon in other joints such as the shoulder and hip joints 
and potentially affects all synovial joints [1, 2]. OA is 
the most common form of arthritis and is a leading cause 
of morbidity and chronic disability. Prevalence of OA 
increases with age: worldwide estimates are that 9.6% of 
men and 18.0% of women over 60 years have sympto-
matic OA. Eighty percent of people affected by OA expe-
rience limitations in movement, and 25% cannot perform 
their major daily life activities [3]. The main pathophysi-
ological event is the thinning of cartilage in joints which 
results in bones rubbing together, causing stiffness, pain, 
and impaired movement with reduced quality of life and 
significant social and economic burden [4, 5]. Although 
research has focused primarily on the alterations in joint 
cartilage and synovial film, there is increasing evidence 
of involvement of all joint tissues [6]. The main goals in 
OA treatments are to relief pain, to slow the progression 
of joint structure modifications and to improve functional 
limitation and quality of life [7, 8]. Global strategies 
aim to reduce the burden of musculoskeletal disease and 
promote healthy ageing tailored to meet the individual 
patient’s needs [9]. The recent European Society for Clini-
cal and Economic Aspects of Osteoporosis, Osteoarthritis 
and Musculoskeletal Diseases (ESCEO) guideline for the 
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management of OA [10] recommend a combination of 
non-pharmacologic and pharmacologic measures (Fig. 1).
Fast-acting symptom modifying drugs include tra-
ditional analgesics (e.g. paracetamol, tramadol etc.), 
non-steroidal anti-inflammatory drugs (NSAIDs) and 
intra-articular corticosteroids. These substances induce a 
fast relief of symptoms and improve joint function [11]. 
However, they are not devoid of toxicity and when used 
chronically their gastrointestinal, liver, kidney and hae-
matological side effects (sometimes serious) can be clini-
cally important and associated to high costs, particularly in 
the elderly. Slow-acting drugs for the treatment of OA are 
defined as symptom modifying (Symptomatic Slow Acting 
Drugs of OA, SYSADOA). This group includes drugs that 
can be administered systemically (e.g. chondroitin sulfate 
CS, glucosamine GlcN sulfate, diacerein), as well as sub-
stances that can be administered intra-articularly (hyalu-
ronic acid). Chondroitin sulfate oral supplementation is 
recommended by ESCEO and other European guidelines 
[10, 12, 13] as background treatment to reduce joint pain 
and improve functional impairment in OA patients. Chem-
ically, CS monomer is a disaccharide molecule constituted 
by N-acetylgalactosamine and glucuronic acid; The sulfate 
group in CS can be linked to the galactosamine moiety in 
two positions—4 or 6—which explains the existence of 
two isomers (Fig. 2).
Chondroitin sulfate is usually derived from bovine, por-
cine, chicken or fish cartilage sources by extraction and 
purification procedures. Several clinical studies, as reported 
in the review by Chevalier and Conrozier [11] the meta-
analysis by Hochberg et al. [15], Hochberg [15] and Honvo 
et al. [16, 17] demonstrated that CS at the marketed unit 
dose strengths (400 mg, 800 mg and 1200 mg) exerts an 
important activity on the mitigation of pain caused by OA, 
particularly knee, hand and hip OA; CS induces an improve-
ment of algo-functional scores with a very low risk of toxic-
ity reported in post-marketing surveillance data.
Considering the important role played by CS in the treat-
ment of OA, we aimed to review the existing evidence on 
highly purified chondroitin sulfate (hpCS)  (Condrosulf® 
IBSA), a prescription drug containing highly purified chon-
droitins 4 and 6 sulfate in a concentration not less than 95%. 
We grouped the evidence by involved joint, adding specific 
discussion for the new dosage of hpCS 1200 mg, for the 
comparison with food supplements and for pharmacoeco-
nomic aspects.
Materials and methods
The MEDLINE and PubMed databases were searched for 
randomized controlled trials (RCTs), meta-analyses, system-
atic reviews and review articles on hpCS in OA published 
between 1992 and 2020. The search strategy was based on 
carefully constructed review questions and was performed 
using the appropriate clinical terms to identify all papers 
containing information on hpCS efficacy and safety and to 
address specific questions relevant to the dosage as well as 
pharmacoeconomic aspects. PICO evidence-based model 
[18] was used for framing a question, locating, assessing, 
evaluating and repeating as needed. PICO keywords are 
focused on:
• Problem/patient/population: people with osteoarthritis.
• Intervention: chondroitin sulfate.
• Comparison: placebo/no intervention.
• Outcomes: pain and function.
The literature searches included the terms: ‘chondroitin 
sulfate’, ‘pharmaceutical-grade’, ‘highly purified’, ‘osteo-
arthritis’ ‘knee osteoarthritis’, ‘hip osteoarthritis’, ‘hand 
osteoarthritis’, ‘food supplement’ ‘pharmacoeconomy’. The 
references of retrieved paper were manually searched for 
additional relevant articles and guidelines and OA treatment 
recommendations were also considered.
Pharmacokinetics
The structure and characteristics of hpCS, such as molecu-
lar mass, charge density (in terms of electrostatic properties 
related to sulfated and nonsulfated disaccharides) and cluster 
of disulfated disaccharides can strongly influence its absorp-
tion and bioavailability. The pharmacokinetic (PK) charac-
teristics of oral hpCS were evaluated in healthy volunteers 
[19, 20]. In a study by Conte et al. [20] hpCS was given to 
12 healthy volunteers in fasting conditions as a single dose 
or two 400 mg doses at a 12-h interval. Table 1 summarizes 
the results of the main PK parameters in this study. 
Twenty-four hours after oral administration, a high con-
centration was found in the intestine, liver and kidneys, 
organs involved in the breakdown and the excretion of oligo- 
and polysaccharides, but also in the synovial fluid and car-
tilages, where the molecule tends to accumulate [21, 22].
Pharmacodynamics
The pharmacodynamics of CS is extensively studied. 
Bassleer et  al. [23] found that in chondrocytes, hpCS 
antagonizes interleukin-1(IL-1)-induced increases in p38 
Fig. 1  Updated ESCEO stepwise treatment algorithm for knee osteo-
arthritis. COX-2, cyclooxygenase-2; CS, chondroitin sulfate; CV, car-
diovascular; GI, gastrointestinal; GS, glucosamine sulfate; IA, intra-
articular; NSAID, non-steroidal anti-inflammatory drug; PPI, proton 
pump inhibitor; SYSADOA, symptomatic slow-acting drugs in osteo-
arthritis; OA, osteoarthritis. Reproduced from Bruyère et al. [10] with 
permission from BMJ Publishing Group Ltd
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mitogen-activated protein kinase (p38MAPK) and signal-
regulated kinase 1/2 (Erk1/2) phosphorylation and decreases 
in nuclear factor-B (NFB) nuclear translocation and as a con-
sequence reduced formation of pro-inflammatory cytokines, 
IL-1 and TNF, and pro-inflammatory enzymes, such as 
phospholipase A2 (PLA2), cyclooxygenase 2 (COX-2) and 
nitric oxide synthase-2 (NOS-2). The mechanism of action 
of CS explains its beneficial effect on the cartilage, synovial 
membrane and subchondral bone. In vivo, hpCS given p.o. 
prevented hepatic NFB nuclear translocation and this sug-
gested that systemic hpCS could elicit an anti-inflammatory 
effect in many tissues besides the articulation. On this basis, 
Ronca et al. [24] and Cohen et al. [25] reported that hpCS 
could be useful also in other inflammatory diseases, like 
psoriasis and atherosclerosis. Jomphe et al. [26] observed 
that the beneficial effects of hpCS in patients with OA result 
partially from its antinflammatory and immunomodulatory 
actions, as the reduction of NFB nuclear translocation, the 
decrease in the synthesis of pro-inflammatory cytokines 
IL-1 and TNF and in the activity of NOS-2 and COX-2. 
Other actions of hpCS contribute to its activity, such as the 
increase in the synthesis of articular cartilage PG, the reduc-
tion in the apoptosis of chondrocytes and the reduction of 
the synthesis and/or activity of MMPs [27–32].
Clinical evidence on highly purified chondroitin 
sulfate
Table 2 summarizes the clinical evidence on hpCS in OA, 
preclinical studies and meta-analyses discussed are not 
included.
Hip and knee OA
Conrozier and Vignon [33] in their study on hip OA used 
eight parameters: (1) Huskisson’s Visual Analogue Scale 
(VAS); (2) Lequesne’s Index (LI); (3) analgesic consump-
tion; (4) morning stiffness; (5) walking autonomy; (6) 
awakenings during the night, (7) intramalleolar distance, 
(8) patient evaluation. Parameters 1, 2, 3 and 8 were con-
sidered as essential. The hpCS group showed a statistically 
significant improvement compared to the placebo (PLB) in 
all essential parameters. Figure 3 shows the evolution of pain 
measured by the VAS.
As for knee OA, Uebelhart et al. [34, 35] conducted a 
pilot study and a RCT. In the pilot study, hpCS was asso-
ciated with a stabilization of the medial femorotibial joint 
space width (JSW). The study evaluated also biomarkers 
of bone formation (osteocalcin), aggrecan (serum anti-
gentic keratan sulfate) and connective tissue (urinary pri-
dinolyne) degradation. The parameters were stabilized in 
hpCS patients, whilst they remained abnormal in the PLB 
group. In the subsequent RCT, LI decreased significantly 
by 36% in the hpCS group after 1 year compared to 23% 
in the PLB group (p = 0.001). Radiological progression 
at month 12 showed a significant decrease of JSW in the 
PLB group, whilst there were no changes in the hpCS 
group (p < 0.05). The authors concluded that, in addition 
to the actions on signs and symptoms, the effect of hpCS 
on the JSW narrowing provided further evidence of the 
structure-modifying properties of hpCS in knee OA. In his 
study, Michel et al. [36] found that 150 patients receiving 
PLB showed a progressive JSW narrowing, with a mean 
JSW loss of 0.14 ± 0.61 mm after 2 years (p = 0.001). The 
150 patients treated with hpCS did not show any change 
in mean JSW (0.00 ± 0.53 mm; p NS); the minimum JSW 
narrowing showed a similar trend. The differences between 
groups were significant for mean (0.14 ± 0.57 mm; p = 0.04) 
and minimum JSW (0.12 ± 0.52 mm; p = 0.05). The study 
demonstrated that hpCS may slow the structural progres-
sion of knee OA. In a prospective, open study, Radrigàn 
et al. [37] observed at day 90 an improvement of 44.4% in 
the LI (p < 0.0001) and of 56.8% (right) and 61.7% (left) in 
the knee pain measured by VAS. At day 180 (90 days after 
the last administration of hpCS) the parameters were still 
significantly better than the basal levels. The residual effect 
was more marked in patients < 65 years and in those with 
less basal radiological damage. Kahan et al. [38] studied 
Fig. 2  Formula of CS monomer
Table 1  Pharmacokinetic parameters after oral administration of 
800 mg hpCS.  Modified from Conte et al. [20]
a After administration of the first 400 mg dose
b After administration of the second 400 mg dose
PK parameter 800 mg single dose 
(mean ± SD)
400 mg + 400 mg 
dose (mean ± SD)
Cmax (μg/ml) 2.6 ± 0.5 1.2 ± 0.2a
tmax (h) 5.0 ± 1.0 5.2 ± 1.0a
t½ (h) 10.3 ± 6.8 10.3 ± 2.5b
AUC 0–12h (μg h/ml) 23.9 ± 4.2 10.6 ± 1.7
AUC ∞ (μg h/ml) 46.8 ± 10.1 37.3 ± 9.4
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56 hpCS 3 × 400 mg/day
PLB
6 months
Pain (VAS); LI; analgesic consumption; patient’s assessment, 







Pain and overall mobility (VAS) at 3 (p < 0.05) and 12 





2 × 3 months during 1 year
hpCS: more LI decrease (36% hpCS vs 23% PLB;  











61 hpCS 800 mg/day for 3 months
follow-up: 6 months
Improvement of 44.4% in the LI (p < 0.0001) and of 56.8% 






Reduction in JSW loss with hpCS (p < 0.0001 vs. PLB); 







hpCS better than PLB in pain at VAS (p < 0.01), LI (p < 0.05) 








Less cartilage volume loss in hpCS than in PLB group 
(p = 0.03). Lower subchondral BML scores in hpCS group 
at 12 months (lateral compartment  p = 0.035; lateral con-






hpCS significantly reduced synovitis compared to paraceta-
mol (p < 0.01)







At day 182 pain (VAS) reduced (p = 0.001 hpCS;  p = 0.009 





34 hpCS 3 × 400/day
PLB
18 months
hpCS reduced pain (VAS) and improved hand function
Verbruggen 1998 [44]
RCT 
119 hpCS 3 × 400 mg/day
PLB
3 years




24 hpCS 800 mg/day + naproxen 500 mg/day
naproxen 500 mg/day
24 months
hpCS + naproxen lower increase in number of joints with ero-
sions (p < 0.05)
Rovetta 2004 [46]
RCT 
24 hpCS 800 mg/day + naproxen 500 mg/day
naproxen 500 mg/day
24 months
hpCS + naproxen better than naproxen in Heberden 
(p < 0.001) and Dreiser (p < 0.001) scores, in patient’s 






Significant decrease in the patient’s global assessment of 
hand pain (difference VAS scores − 8.7 mm;  p = 0.016) 
and significant improvement in FIHOA score (− 2.14;  
p = 0.008) in hpCS group vs placebo
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the effects of hpCS on the progression of knee OA. The 
hpCS group had a reduced loss of minimum JSW compared 
with the PLB group (− 0.07 ± 0.03 mm vs − 0.31 ± 0.04 mm 
p < 0.0001). The percentage of patients with radiographic 
progression > 0.25 mm was lower in the hpCS than in PLB 
group [28% vs 41% (p < 0.0005); with a relative risk reduc-
tion of 33% (95% CI 16–46%)]. The number of patients 
needed to treat was eight (95% CI 5–17). Pain improved 
faster in the hpCS than in the PLB group (p < 0.01).
Möller et al. [39] found that after 3 months hpCS resulted 
more effective than PLB, relieving pain at VAS (hpCS 
− 26.9 ± 24.8; PLB − 14.23 ± 20.8 mm, p < 0.01), decreas-
ing the LI (hpCS − 4.8 ± 3.4; PLB − 3.3 ± 3.5, p < 0.05) 
and reducing the use of paracetamol as rescue medica-
tion (hpCS 43%; PLB 64%, p < 0.05). hpCS improved also 
signs of plantar psoriasis more than PLB (hpCS 87%; 
PLB 27%, p < 0.05). In the RCT by Wildi et al. [40], hpCS 
group showed significantly less cartilage volume loss than 












146 hpCS 3 × 400 mg/day
diclofenac 3 × 50 mg/day;
3 months + 3 months follow-up
LI hpCS − 64.4%; diclofenac vs − 29.7% vs baseline; par-




127 hpCS gel 1 × 1200 mg/day
hpCS 3 × 400 mg/day
PLB
3 months
hpCS 1 × 1200 and 3 × 400 lower than PLB in LI (p < 0.0001 
at day 91) and pain (VAS) (hpCS 1 × 1200  p < 0.01 from 








hpCS 2 × 400 and 3 × 400 mg/die more effective than 
200 mg/die and PLB on LI (p < 0.01); pain at VAS 




1583 hpCS 3 × 400 mg/day





Response rate, percent difference from PLB
GlcN + 3.9% (p = 0.30),
hpCS: + 5.3% (p = 0.17),
GlcN + hpCS: % 6.5% (p = 0.09)
celecoxib: + 10.0% (p = 0.008)
Zegels 2013 [52]
RCT 
353 hpCS 1 × 1200 mg/day
3 × 400 mg/day
PLB
hpCS 1200 mg or hpCS 3 × 400 mg/day significantly 
improved compared to PLB in terms of LI (p < 0.001) and 
VAS for spontaneous pain (p < 0.01)
Pelletier 2016 [53]
RCT 
114 hpCS 3 × 400 mg/day
celecoxib 200 mg/day
2 years
hpCS showed less cartilage loss than celecoxib in medial 
compartment (p = 0.018) and medial condyle (p = 0.008)
IBSA 2019
RCT 
246 hpCS 1 × 1200 mg/day
hpCS 3 × 400 mg/day
91 days
hpCS 1200 mg once daily not inferior to hpCS 3 × 400 mg/
day in LI (− 2.9 ± 0.3; − 2.6 ± 0.3, respectively;  




94 hpCS 1 × 1200 mg/day
hpCS 3 × 400 mg/day
PLB
91 days
Mean (± SD) decrease of LI from baseline to day 91: − 4.3 
(3.3) in the hpCS 1200 mg group, − 4.1 (2.9) in the hpCS 















Recent (< 3 months) users
Lower consumption of NSAIDs (p < 0.05) and analgesics 








Treatment cost 6-month: CS €141; NSAIDs €182. Concomi-
tant CS could reduce use of NSAIDs
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the PLB group as early as 6 months for the global knee 
(p = 0.030), the lateral compartment (p = 0.015) and tibial 
plateaus (p = 0.002). The difference remained significant at 
12 months. Significantly lower subchondral bone marrow 
lesions scores were found for the hpCS group at 12 months 
in the lateral compartment (p = 0.035) and the lateral femo-
ral condyle (p = 0.044). Montfort [41] focused his study on 
synovitis. HpCS but not paracetamol reduced synovitis and 
symptoms in OA patients. The study showed also a decrease 
in synovial and plasma levels of inflammatory chemokines 
in hpCS group. In his RCT, Reginster et al. [42] observed 
that hpCS and celecoxib showed a significant reduction in 
pain and LI compared with PLB. In the intention-to-treat 
(ITT) population, pain reduction at VAS at day 182 was sig-
nificantly greater in the hpCS group (− 42.6 mm) and in the 
celecoxib group (− 39.5 mm) than in PLB group (− 33.3 mm, 
p = 0.001 hpCS; p = 0.009 celecoxib), without difference 
between hpCS and celecoxib (Fig. 4). The improvement of 
LI was greater in the hpCS (− 4.7) and celecoxib (− 4.6) than 
in the PLB group (− 3.7) (p = 0.023 for HPCS; p = 0.015 
for celecoxib). No difference was observed between hpCS 
and celecoxib. The secondary endpoints: Minimal-Clinically 
Important Improvement (MCII) and Patient-Acceptable 
Symptoms State (PASS), showed significant improvement 
in the hpCS and celecoxib groups compared to PLB.
Hand OA
Wang et al. [43] on 34 patients found that the treatment with 
hpCS reduced pain and improved function of the hand with-
out impact on radiological signs. In the RCT by Verbruggen 
et al. [44], hpCS group reported a significant decrease in the 
number of patients with new erosive OA lesions in the finger 
joints. In two RCTs, Rovetta et al. [45, 46] observed a sig-
nificant difference in favour of the hpCS + naproxen group 
compared to naproxen only in number of joints with erosions 
(p < 0.05), a superiority of hpCS in Heberden (p < 0.001) 
and Dreiser (p < 0.001) scores and in patient’s (p < 0.001) 
and clinician’s (p < 0.001) judgement. Gabay et al. [47] 
found that, compared with PLB, patients treated with hpCS 
showed a significant decrease in the patient’s global assess-
ment of pain (difference VAS scores − 8.7 mm; p = 0.016). 
The hpCS group showed also a significant improvement in 
Functional Index for Hand OsteoArthritis (FIHOA) score 
(− 2.14; p = 0.008), in morning stiffness and in the investiga-
tor’s global impression of efficacy.
Condrosulf 1200 mg/day
The recommended dose of hpCS is 800 mg/day; yet in the 
most severe cases an initial dose of 1200 mg/day is advis-
able for the first weeks of treatment, which is then followed 
Fig. 3  Reduction of pain in 
hip measured by a VAS scale; 
*p < 0.01, **p < 0.001, NS Not 
Significant; drawn based on 
data reported in Conrozier and 
Vignon [33]
Fig. 4  Reduction of pain in knee measured by a VAS scale. Repro-
duced from Reginster et al. [42] with permission from Elsevier
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by a reduction of the dose to 800 mg. Morreale et al. [48], 
comparing hpCS with diclofenac observed that diclofenac 
had a faster effect, but the treatment with hpCS 3 × 400 mg/
day was associated with longer-lasting symptomatic efficacy, 
with a lower LI from day 60 to day 180. Bourgeois et al. 
[49] found that the physician’s and patient’s overall efficacy 
assessments were superior for hpCS than PLB (p < 0.001). 
The efficacy of hpCS 1200 oral gel mg once daily did not 
differ from that of hpCS 3 × 400 mg/day. Pavelka et al. [50] 
studied three dosages of hpCS and found that hpCS at 800 
and 1200 mg/day was more effective than PLB without 
difference between the two doses, whilst hpCS 200 mg/
day was not different form PLB. Clegg et al. [51] reported 
that hpCS and GlcN, alone or in combination, had a mod-
est effect on pain reduction compared to PLB, which was 
associated with a high rate of response. Despite the marked 
PLB effect, the response rate to hpCS in monotherapy was 
5.3% points higher than PLB. In the RCT by Zegels et al. 
[52], after 3 months, no significant difference was observed 
between hpCS 1200  mg oral gel once daily and hpCS 
3 × 400 mg/day. Patients treated with hpCS 1 × 1200 mg/
day or 3 × 400 mg/day significantly improved compared to 
PLB in terms of LI (p < 0.001) and VAS for spontaneous 
pain (p < 0.01). Pelletier et al. [53] demonstrated that hpCS 
was superior than celecoxib in reduction of cartilage volume 
loss measured by magnetic resonance. HpCS and celecoxib 
were similarly effective in improving joint effusion and/or 
swelling, WOMAC total score, WOMAC pain score, pain 
assessed by VAS and quality of life (Short Form-36). Two 
phase III, multicenter RCTs (IBSA, data on file) evaluated 
the efficacy and safety of hpCS 1200 mg oral gel once daily 
vs hpCS 3 × 400 mg/day. The first study showed that hpCS 
1200 mg once daily was not inferior to hpCS 3 × 400 mg/day 
in LI (− 2.9 ± 0.3; − 2.6 ± 0.3, respectively; p < 0.0001). No 
significant difference between groups was observed regard-
ing pain, NSAIDs consumption or patient and investigator 
global assessment of efficacy. The second study confirmed 
these evidences. The improvement in LI and the decrease in 
pain were significantly greater in both hpCS groups com-
pared to PLB, without differences between the two hpCS 
formulations.
Safety
The overall analysis of all the studies included in this review, 
provided evidence that hpCS formulations have a good 
safety profile. The incidence and severity of hpCS-related 
adverse events (AEs) are low and similar to those of the 
placebo also at the dosage of 1200 mg/day. Gastrointestinal 
disorders were the most common AEs and were reported 
more in patients of the PLB group than in those of the two 
hpCS groups with statistically significant differences. Both 
patients and investigators expressed an excellent/good opin-
ion of safety in the vast majority of cases. These data are 
consistent with the worldwide post-marketing data from 
Europe, Middle East, North and South America since 1982 
(IBSA data on file).
Chondroitin sulfate versus food supplements
Food supplements (FS) do not undergo the strict quality con-
trols of pharmaceuticals, because of loose regulatory con-
straints; this raises concerns about their safety and clinical 
efficacy. As stated in the position paper endorsed by ESCEO 
[54], only pharmaceutical CS is shown to deliver consist-
ently high CS bioavailability and plasma concentration in 
humans, which corresponds to demonstrated clinical effi-
cacy. Volpi and Maccari [55] assessed the amount, quality 
and origin of CS from ten Czech Republic FS preparations. 
Only four of the ten preparations met the label specifica-
tions. Other four preparations contained between 0 and 1% 
CS in comparison with the contents declared on the label 
(47%, 17%, 12%, 6%). Two preparations had 30–45% of the 
declared content of CS, and one contained approximately 2% 
HA. The CS contained in eight FS was bovine or porcine, 
in one preparation CS derived from cartilaginous fish and 
in one case CS levels were too low for any determination.
Restaino et al. [56] examined 25 FS preparations from 
eight European countries by multiple analytical methods 
(high performance chromatography, nuclear magnetic 
resonance, capillary electrophoresis) and biological assays 
(action on chondrocyte culture). The FS were then com-
pared to two pharmaceutical CS products. Compared to the 
pharmaceutical-grade products, FS contained low-quality 
CS, in some cases of multiple animal origins and of dis-
homogeneous molecular weights. The FS resulted to be 
highly contaminated by keratan sulfate; the presence of 
high insoluble solids and solvent residues was suggestive of 
poorly controlled manufacturing procedures or low-quality 
raw materials used in the FS preparations. Stellavato et al. 
[57] assessed the purity, the titer, and the origin of ten dif-
ferent FSs containing CS and then compared their biological 
activity with two pharmaceutical CS products. The pharma-
ceutical-grade products demonstrated an effective modula-
tion of biomarkers counteracting the inflammation status and 
improving viability and the physiological condition of OA 
human primary chondrocytes and synoviocytes. In contrast, 
most FSs were cytotoxic at the tested concentrations, and 
only three out of ten FSs had an in vitro behaviour similar 
to that of the pharmaceutical-grade products.
The results of the above mentioned researches demon-
strate the need for stricter rules to control the quality of FSs 
to obtain safe and effective products.
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Pharmacoeconomy
HpCS was comprehensively studied from the pharmacoeco-
nomic point of view. Bruyère et al. [58] in a 2-year RCT, 
evaluated the impact of hpCS on health-related quality 
of life using utility values in patients with knee OA. The 
Health Utility Index (HUI) score changes from baseline to 
6 months were 0.02 ± 0.02 and 0.05 ± 0.01 for the PLB and 
hpCS groups, respectively (p = 0.03). After 24 months, the 
HUI score increased by 0.04 ± 0.02 in the PLB group and 
0.05 ± 0.02 in the hpCS group (p = 0.37). Considering the 
price of hpCS in Europe, the cost effectiveness ratio assess-
ment always resulted in a cost below € 30,000 per quality-
adjusted-life-year (QALY) gained, after 6, 12 and 24 months 
of treatment. Lagnaoui et al. [59] studied the impact of the 
use of hpCS 400 mg on the consumption of analgesics and 
NSAIDs. Patients with OA (844) OA were divided in “recent 
hpCS users” (≤ 30 days of continuous use; 222 pat.) and 
“long-term hpCS users” (> 30 days of continuous use; 622 
pat). Ninety-eight (11.6%) patients did not use any anal-
gesic or NSAIDs; 746 (88.4%) reported the use of at least 
one of these drugs. Compared to recent users, long-term 
users of hpCS400 had a significantly lower current (44.4 vs. 
52.5%, p < 0.05) and long-term use of NSAIDs (11.8% ver-
sus 18.5%, p < 0.05) and of analgesics (70.3 versus 79.3%, 
p < 0.01). The results suggested that the use of hpCS could 
reduce the consumption of NSAIDs. The retrospective study 
conducted by Rubio-Terrés [4] (data from the VECTRA 
study) evaluated the economic impact of the treatment with 
hpCS or NSAIDs. The use of hpCS in 530 patients with OA 
for more than 6 months reduced the use of NSAIDs. The 
overall 6-month cost per patient was 141€ for CS and 182€ 
for NSAIDs. The authors estimated that in 3 years a gradual 
shift to hpCS of 5%, 10%, and 15% of patients currently 
treated with NSAIDs could generate 38,700,000€ savings 
for the Spanish National Health System. In addition, the 
authors calculated that, for every 10,000 patients switching 
from NSAIDs to hpCS 2666 cases of gastrointestinal AEs 
(including 90 SAE) could be avoided.
Discussion
This paper provides an updated and comprehensive over-
view of efficacy, safety, quality and health economics 
impact of the treatment with hpCS  (Condrosulf®, IBSA). 
In addition to this, unpublished efficacy data on the new 
formulation oral gel 1200 mg once daily are presented. The 
main limit of the paper lies in the different design, size and 
assessment measures (e.g. radiological techniques) of indi-
vidual trials; especially the methods of older studies were 
hampered by the period of their publication. The review 
of the scientific literature has raised some points that in 
our opinion deserve further investigation: characteristics 
of the structural progression of the disease and the most 
appropriate methods to assess and quantify it; the role of 
the treatment with hpCS combined with other SYSADOAs 
(e.g. intra-articular hyaluronic acid) or NSAIDs; biomark-
ers or predictors of response to treatment with hpCS.
Conclusion
Highly purified CS, at 400 mg, 800 mg and 1200 mg was 
extensively studied. It proved to be safe and effective in hip, 
knee and hand OA, acting on signs, symptoms and structural 
changes. The use of hpCS reduced the use of NSAIDs and 
their side effects. Furthermore, the use of hpCS was found 
to be cost-effective up to a period of 24 months. It is also 
important to point out that the quality of hpCS is the pre-
requisite for safe and effective preparations.
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